High Prevalence of Co-Infections by Invasive and Non-Invasive Chlamydia trachomatis Genotypes during the Lymphogranuloma Venereum Outbreak in Spain

PLoS One. 2015 May 12;10(5):e0126145. doi: 10.1371/journal.pone.0126145. eCollection 2015.

Abstract

The evolution of Chlamydia trachomatis is mainly driven by recombination events. This fact can be fuelled by the coincidence in several European regions of the high prevalence of non-invasive urogenital genotypes and lymphogranuloma venereum (LGV) outbreaks. This scenario could modify the local epidemiology and favor the selection of new C. trachomatis variants. Quantifying the prevalence of co-infection could help to predict the potential risk in the selection of new variants with unpredictable results in pathogenesis or transmissibility. In the 2009-2013 period, 287 clinical samples with demonstrated presence of C. trachomatis were selected. They were divided in two groups. The first group was constituted by 137 samples with C. trachomatis of the LGV genotypes, and the second by the remaining 150 samples in which the presence of LGV genotypes was previously excluded. They were analyzed to detect the simultaneous presence of non-LGV genotypes based on pmpH and ompA genes. In the first group, co-infections were detected in 10.9% of the cases whereas in the second group the prevalence was 14.6%, which is the highest percentage ever described among European countries. Moreover, bioinformatic analyses suggested the presence among men who have sex with men of a pmpH-recombinant variant, similar to strains described in Seattle in 2002. This variant was the result of genetic exchange between genotypes belonging to LGV and members of G-genotype. Sequencing of other genes, phylogenetically related to pathotype, confirmed that the putative recombinant found in Madrid could have a common origin with the strains described in Seattle. Countries with a high prevalence of co-infections and high migration flows should enhance surveillance programs in at least their vulnerable population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Outer Membrane Proteins / genetics
  • Chlamydia trachomatis / classification*
  • Chlamydia trachomatis / genetics*
  • Chlamydia trachomatis / isolation & purification
  • Coinfection / epidemiology*
  • Disease Outbreaks
  • Female
  • Genome, Bacterial
  • Genotype
  • Homosexuality, Male / genetics
  • Humans
  • Lymphogranuloma Venereum / epidemiology
  • Lymphogranuloma Venereum / microbiology*
  • Male
  • Molecular Sequence Data
  • Phylogeny
  • Prevalence
  • Spain / epidemiology

Substances

  • Bacterial Outer Membrane Proteins
  • PmpH protein, Chlamydia trachomatis
  • OMPA outer membrane proteins

Associated data

  • GENBANK/KM096869
  • GENBANK/KM096870
  • GENBANK/KM096871
  • GENBANK/KM096872
  • GENBANK/KM096873
  • GENBANK/KM096874
  • GENBANK/KM096875
  • GENBANK/KM096876
  • GENBANK/KM096877
  • GENBANK/KM096878
  • GENBANK/KM096879
  • GENBANK/KM096880
  • GENBANK/KM096881
  • GENBANK/KM096882
  • GENBANK/KM096883
  • GENBANK/KM096884
  • GENBANK/KM096885
  • GENBANK/KM096886
  • GENBANK/KM096887
  • GENBANK/KM096888
  • GENBANK/KM096889
  • GENBANK/KM096890
  • GENBANK/KM096891
  • GENBANK/KM096892
  • GENBANK/KM096893
  • GENBANK/KM096894
  • GENBANK/KM096895
  • GENBANK/KM096896
  • GENBANK/KM096897
  • GENBANK/KM096898
  • GENBANK/KM096899
  • GENBANK/KM096900
  • GENBANK/KM096901
  • GENBANK/KM096902
  • GENBANK/KM096903
  • GENBANK/KM096904
  • GENBANK/KM096905
  • GENBANK/KM096906
  • GENBANK/KM096907
  • GENBANK/KM096908
  • GENBANK/KM096909
  • GENBANK/KM096910
  • GENBANK/KM096911
  • GENBANK/KM096912
  • GENBANK/KM096913
  • GENBANK/KM096914
  • GENBANK/KM096915
  • GENBANK/KM096916
  • GENBANK/KM096917
  • GENBANK/KM096918
  • GENBANK/KM096919
  • GENBANK/KM096920
  • GENBANK/KM096921
  • GENBANK/KM096922
  • GENBANK/KM096923
  • GENBANK/KM096924
  • GENBANK/KM096925
  • GENBANK/KM096926
  • GENBANK/KM096927
  • GENBANK/KM096928
  • GENBANK/KM096929
  • GENBANK/KM096930
  • GENBANK/KM096931
  • GENBANK/KM096932
  • GENBANK/KM096933
  • GENBANK/KM096934
  • GENBANK/KM096935
  • GENBANK/KM096936
  • GENBANK/KM096937
  • GENBANK/KM096938
  • GENBANK/KM096939
  • GENBANK/KM096940
  • GENBANK/KM096941
  • GENBANK/KM096942
  • GENBANK/KM096943
  • GENBANK/KM096944
  • GENBANK/KM096945
  • GENBANK/KM096946
  • GENBANK/KM096947
  • GENBANK/KM096948
  • GENBANK/KM096949
  • GENBANK/KM096950
  • GENBANK/KM096951
  • GENBANK/KM096952
  • GENBANK/KM096953
  • GENBANK/KM096954
  • GENBANK/KM096955
  • GENBANK/KM096956
  • GENBANK/KM096957
  • GENBANK/KM096958
  • GENBANK/KM096959
  • GENBANK/KM096960
  • GENBANK/KM096961
  • GENBANK/KM096962
  • GENBANK/KM096963
  • GENBANK/KM096964
  • GENBANK/KM096965
  • GENBANK/KM096966
  • GENBANK/KM096967
  • GENBANK/KM096968

Grants and funding

MRD's work is supported by a contract of the Spanish Network Research Infectious Disease (REIPI), Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, and cofinanced by the European Development Regional Fund “A way to achieve Europe” (ERDF).